{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T08:17:15Z","timestamp":1782980235096,"version":"3.54.5"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Chemoradiotherapy (CRT) with high-dose cisplatin (CDDP) is the standard treatment for locally advanced head and neck squamous cell carcinoma (HNSCC). Although dosing is based on body surface area (BSA), some patients experience CDDP-related adverse events (AEs). We aimed to evaluate the impact of relative CDDP dose to skeletal muscle mass (SMM) on chemotherapy-associated AEs in patients with HNSCC undergoing CRT with high-dose CDDP.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>We retrospectively analyzed data of patients who underwent CRT with high-dose CDDP (80-100 mg\/m2, triweekly) between 2010 and 2023. SMM was measured as the cross-sectional muscle area at the third cervical vertebra (C3-SMM) using computed tomography; the skeletal muscle index (SMI) was defined as SMM normalized by squared height. The CDDP index was defined as the prescribed CDDP dose divided by SMI. CDDP-related AEs were assessed during the first cycle using Common Terminology Criteria for Adverse Events v5.0.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 306 patients were identified. The CDDP index cutoff value best associated with grade\u2005\u2265\u20053 AEs was 10.312. Grade\u2005\u2265\u20053 hematological toxicities exhibited stronger association with high CDDP index value than with low CDDP index value (26.9% vs 16.3%, P\u2005=\u2005.033). Multivariate analysis revealed that high CDDP index value and creatinine clearance\u2005&amp;lt;\u200570 mL\/minute were predictive factors for grade\u2005\u2265\u20053 AEs (odds ratio [OR] 2.55, P\u2005=\u2005.008; OR 3.68, P\u2005=\u2005.002, respectively).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The CDDP index based on C3-SMM was an independent predictive factor for grade\u2005\u2265\u20053 CDDP-related AEs. C3-SMM is potentially more useful than BSA for determining the optimal CDDP dose in patients with HNSCC.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyae167","type":"journal-article","created":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T11:21:28Z","timestamp":1720524088000},"page":"e1315-e1323","source":"Crossref","is-referenced-by-count":2,"title":["Impact of relative cisplatin dose to skeletal muscle mass on adverse events in patients with head and neck cancer undergoing chemoradiotherapy"],"prefix":"10.1093","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6591-2911","authenticated-orcid":false,"given":"Satoshi","family":"Suzuki","sequence":"first","affiliation":[{"name":"Division of Gastrointestinal Oncology, Shizuoka Cancer Center , Shizuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7327-7949","authenticated-orcid":false,"given":"Tomoya","family":"Yokota","sequence":"additional","affiliation":[{"name":"Division of Gastrointestinal Oncology, Shizuoka Cancer Center , Shizuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akifumi","family":"Notsu","sequence":"additional","affiliation":[{"name":"Department of Clinical Research Center, Shizuoka Cancer Center , Shizuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Hamauchi","sequence":"additional","affiliation":[{"name":"Division of Gastrointestinal Oncology, Shizuoka Cancer Center , Shizuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Onozawa","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Shizuoka Cancer Center , Shizuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiro","family":"Fushiki","sequence":"additional","affiliation":[{"name":"Division of Gastrointestinal Oncology, Shizuoka Cancer Center , Shizuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotoe","family":"Oshima","sequence":"additional","affiliation":[{"name":"Division of Gastrointestinal Oncology, Shizuoka Cancer Center , Shizuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Division of Gastrointestinal Oncology, Shizuoka Cancer Center , Shizuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3551-7504","authenticated-orcid":false,"given":"Takahiro","family":"Tsushima","sequence":"additional","affiliation":[{"name":"Division of Gastrointestinal Oncology, Shizuoka Cancer Center , Shizuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Yasui","sequence":"additional","affiliation":[{"name":"Division of Gastrointestinal Oncology, Shizuoka Cancer Center , Shizuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Division of Radiation and Proton Therapy Center, Shizuoka Cancer Center , Shizuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Onoe","sequence":"additional","affiliation":[{"name":"Division of Radiation and Proton Therapy Center, Shizuoka Cancer Center , Shizuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Kawatani","sequence":"additional","affiliation":[{"name":"Department of Diagnostic imaging, Shizuoka Cancer Center , Shizuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"Division of Gastrointestinal Oncology, Shizuoka Cancer Center , Shizuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,9]]},"reference":[{"issue":"1","key":"2024100317301465800_CIT0001","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.2003.01.008","article-title":"An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer","volume":"21","author":"Adelstein","year":"2003","journal-title":"J Clin Oncol"},{"issue":"22","key":"2024100317301465800_CIT0002","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa031317","article-title":"Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer","volume":"349","author":"Forastiere","year":"2003","journal-title":"N Engl J Med"},{"issue":"1","key":"2024100317301465800_CIT0003","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","article-title":"Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients","volume":"92","author":"Pignon","year":"2009","journal-title":"Radiother Oncol"},{"issue":"8","key":"2024100317301465800_CIT0004","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1158\/1078-0432.CCR-08-2242","article-title":"Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment","volume":"15","author":"Prado","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2024100317301465800_CIT0005","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1080\/0284186X.2021.1983210","article-title":"Association of body composition with toxicity to first-line chemotherapy and three-year survival in women with ovarian adenocarcinoma","volume":"60","author":"Bruno","year":"2021","journal-title":"Acta Oncol"},{"issue":"3","key":"2024100317301465800_CIT0006","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1016\/j.clnesp.2016.04.001","article-title":"Impact of body composition parameters on clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with docetaxel","volume":"13","author":"Cushen","year":"2016","journal-title":"Clin Nutr ESPEN"},{"issue":"24","key":"2024100317301465800_CIT0007","doi-asserted-by":"crossref","first-page":"4868","DOI":"10.1002\/cncr.30950","article-title":"Muscle mass at the time of diagnosis of nonmetastatic colon cancer and early discontinuation of chemotherapy, delays, and dose reductions on adjuvant FOLFOX: The C-SCANS study","volume":"123","author":"Cespedes Feliciano","year":"2017","journal-title":"Cancer"},{"issue":"7","key":"2024100317301465800_CIT0008","doi-asserted-by":"crossref","first-page":"101580","DOI":"10.1016\/j.jgo.2023.101580","article-title":"Association of sarcopenia with relative dose intensity of neoadjuvant chemotherapy in older patients with locally advanced esophageal cancer: a retrospective cohort study","volume":"14","author":"Harada","year":"2023","journal-title":"J Geriatr Oncol"},{"issue":"6","key":"2024100317301465800_CIT0009","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1753-4887.1991.tb03013.x","article-title":"The meaning and measurement of lean body mass","volume":"49","author":"Roubenoff","year":"1991","journal-title":"Nutr Rev"},{"issue":"8","key":"2024100317301465800_CIT0010","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.oraloncology.2017.05.012","article-title":"Low skeletal muscle mass is a predictive factor for chemotherapy dose-limiting toxicity in patients with locally advanced head and neck cancer","volume":"71","author":"Wendrich","year":"2017","journal-title":"Oral Oncol"},{"issue":"3","key":"2024100317301465800_CIT0011","doi-asserted-by":"crossref","first-page":"317","DOI":"10.21053\/ceo.2018.01613","article-title":"Diagnosis of sarcopenia in head and neck computed tomography: cervical muscle mass as a strong indicator of sarcopenia","volume":"12","author":"Ufuk","year":"2019","journal-title":"Clin Exp Otorhinolaryngol"},{"issue":"22","key":"2024100317301465800_CIT0012","doi-asserted-by":"crossref","first-page":"5536","DOI":"10.3390\/cancers14225536","article-title":"Sarcopenia as a prognostic marker in elderly head and neck squamous cell carcinoma patients undergoing (chemo-)radiation","volume":"14","author":"Haehl","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"7","key":"2024100317301465800_CIT0013","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1007\/s00405-021-07229-y","article-title":"Image-based analysis of skeletal muscle mass predicts cisplatin dose-limiting toxicity in patients with locally advanced head and neck cancer","volume":"279","author":"Chargi","year":"2022","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"2","key":"2024100317301465800_CIT0014","doi-asserted-by":"crossref","first-page":"e0282015","DOI":"10.1371\/journal.pone.0282015","article-title":"Low skeletal muscle mass is predictive of dose-limiting toxicities in head and neck cancer patients undergoing low-dose weekly cisplatin chemoradiotherapy","volume":"18","author":"Becker","year":"2023","journal-title":"PLoS One"},{"issue":"9-10","key":"2024100317301465800_CIT0015","first-page":"1515","article-title":"Pharmacokinetics of non-protein-bound platinum species following administration of cis-dichlorodiammineplatinum II","volume":"63","author":"Belt","year":"1979","journal-title":"Cancer Treatment Rep"},{"issue":"6","key":"2024100317301465800_CIT0016","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/j.1365-2125.2004.02082.x","article-title":"Population pharmacokinetics of total and unbound plasma cisplatin in adult patients","volume":"57","author":"Urien","year":"2004","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"2024100317301465800_CIT0017","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1472-6904-8-7","article-title":"Long-term platinum retention after treatment with cisplatin and oxaliplatin","volume":"8","author":"Brouwers","year":"2008","journal-title":"BMC Clin Pharmacol"},{"issue":"7","key":"2024100317301465800_CIT0018","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1470-2045(08)70153-0","article-title":"Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study","volume":"9","author":"Prado","year":"2008","journal-title":"Lancet Oncol"},{"issue":"11","key":"2024100317301465800_CIT0019","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1158\/1078-0432.CCR-06-3067","article-title":"Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity","volume":"13","author":"Prado","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2024100317301465800_CIT0020","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejca.2021.10.010","article-title":"The association of cisplatin pharmacokinetics and skeletal muscle mass in patients with head and neck cancer: the prospective PLATISMA study","volume":"160","author":"Chargi","year":"2022","journal-title":"Eur J Cancer"},{"issue":"2","key":"2024100317301465800_CIT0021","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.anndiagpath.2011.09.002","article-title":"Is p16 immunohistochemistry a more cost-effective method for identification of human papilloma virus-associated head and neck squamous cell carcinoma","volume":"16","author":"Thomas","year":"2012","journal-title":"Ann Diagn Pathol"},{"issue":"4","key":"2024100317301465800_CIT0022","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/annonc\/mdt574","article-title":"Impact of tumor HPV status on outcome in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial","volume":"25","author":"Vermorken","year":"2014","journal-title":"Ann Oncol"},{"issue":"1","key":"2024100317301465800_CIT0023","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0167-8140(97)01904-X","article-title":"Importance of overall treatment time for the outcome of radiotherapy of advanced head and neck carcinoma; dependency on tumor differentiation","volume":"43","author":"Hansen","year":"1997","journal-title":"Radiother Oncol"},{"issue":"8","key":"2024100317301465800_CIT0024","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1634\/theoncologist.2008-0024","article-title":"Radiation treatment breaks and ulcerative mucositis in head and neck cancer","volume":"13","author":"Russo","year":"2008","journal-title":"Oncologist"},{"issue":"3","key":"2024100317301465800_CIT0025","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.ijrobp.2007.03.010","article-title":"Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation","volume":"68","author":"Bese","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"108","key":"2024100317301465800_CIT0026","first-page":"57","article-title":"Cisplatin based chemoradiation late toxicities in head and neck squamous cell carcinoma patients","volume":"20","author":"Rivelli","year":"2015","journal-title":"Discov Med"},{"issue":"2","key":"2024100317301465800_CIT0027","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1055\/s-0039-1684041","article-title":"A review of cisplatin-associated ototoxicity","volume":"40","author":"Paken","year":"2019","journal-title":"Semin Hear"},{"issue":"4","key":"2024100317301465800_CIT0028","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/hed.26978","article-title":"Poor treatment tolerance in head and neck cancer patients with low muscle mass","volume":"44","author":"Mascarella","year":"2022","journal-title":"Head Neck"},{"issue":"2","key":"2024100317301465800_CIT0029","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1046\/j.1365-2125.2002.01598.x","article-title":"Relationships between body composition parameters and fluorouracil pharmacokinetics","volume":"54","author":"Gusella","year":"2002","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"2024100317301465800_CIT0030","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2217\/bmm-2022-0748","article-title":"Evaluation of sarcopenia as a prognostic biomarker in locally advanced head and neck squamous cell carcinoma","volume":"17","author":"Erul","year":"2023","journal-title":"Biomark Med"},{"issue":"2","key":"2024100317301465800_CIT0031","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1023\/A:1010639201787","article-title":"Body surface area as a determinant of pharmacokinetics and drug dosing","volume":"19","author":"Sawyer","year":"2001","journal-title":"Invest New Drugs"},{"issue":"4","key":"2024100317301465800_CIT0032","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/cam4.621","article-title":"Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens","volume":"5","author":"Ali","year":"2016","journal-title":"Cancer Med"},{"issue":"4","key":"2024100317301465800_CIT0033","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s00520-016-3518-2","article-title":"Can body composition be used to optimize the dose of platinum chemotherapy in lung cancer? A feasibility study","volume":"25","author":"Crosby","year":"2017","journal-title":"Support Care Cancer"},{"issue":"7","key":"2024100317301465800_CIT0034","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1200\/JCO.1998.16.7.2297","article-title":"Body surface area as a basis for dosing of anticancer agents; science, myth, or habit","volume":"16","author":"Ratain","year":"1998","journal-title":"J Clin Oncol"},{"issue":"4","key":"2024100317301465800_CIT0035","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2165\/00003088-199426040-00005","article-title":"Lean Body Mass as a Predictor of Drug Dosage Implications for Drug Therapy","volume":"26","author":"Morgan","year":"1994","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"2024100317301465800_CIT0036","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.3390\/jcm12041423","article-title":"The impact of pre-chemotherapy body composition and immunonutritional markers on chemotherapy adherence in stage III colorectal cancer patients","volume":"12","author":"Lee","year":"2023","journal-title":"J Clin Med"},{"issue":"11","key":"2024100317301465800_CIT0037","doi-asserted-by":"crossref","first-page":"e0294147","DOI":"10.1371\/journal.pone.0294147","article-title":"Low dose cisplatin weekly versus high dose cisplatin every three weeks in primary chemoradiotherapy in head and neck cancer patients with low skeletal muscle mass: The CISLOW-study protocol","volume":"18","author":"Schaeffers","year":"2023","journal-title":"PLoS One"},{"issue":"1","key":"2024100317301465800_CIT0038","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1152\/jappl.1998.85.1.115","article-title":"Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography","volume":"85","author":"Mitsiopoulos","year":"1998","journal-title":"J Applied Physiol"},{"issue":"1","key":"2024100317301465800_CIT0039","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1146\/annurev.nutr.17.1.527","article-title":"Human body composition: advances in models and methods","volume":"17","author":"Heymsfield","year":"1997","journal-title":"Annu Rev Nutr"},{"issue":"13","key":"2024100317301465800_CIT0040","doi-asserted-by":"crossref","first-page":"105617","DOI":"10.1016\/j.oraloncology.2021.105617","article-title":"Validation of skeletal muscle mass assessment at the level of the third cervical vertebra in patients with head and neck cancer","volume":"123","author":"Bril","year":"2021","journal-title":"Oral Oncol"},{"issue":"11","key":"2024100317301465800_CIT0041","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.oraloncology.2016.09.006","article-title":"Feasibility of using head and neck CT imaging to assess skeletal muscle mass in head and neck cancer patients","volume":"62","author":"Swartz","year":"2016","journal-title":"Oral Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/10\/e1315\/59558439\/oyae167.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/10\/e1315\/59558439\/oyae167.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T17:35:31Z","timestamp":1727976931000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/29\/10\/e1315\/7709618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,9]]},"references-count":41,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,7,9]]},"published-print":{"date-parts":[[2024,10,3]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae167","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,7,9]]}}}